Adalimumab:回顾它的使用在类风湿性关节炎。

文章的细节

引用

复制到剪贴板

爆炸LM,基廷通用

Adalimumab:回顾它的使用在类风湿性关节炎。

BioDrugs。2004;18 (2):121 - 39。

PubMed ID

15046527 (在PubMed

]

文摘

Adalimumab(抗)是一个重组,充分人类IgG1单克隆抗体结合具体肿瘤坏死因子(TNF) t1,从而中和细胞因子的活动。皮下adalimumab一直在精心设计的试验研究活跃的风湿性关节炎患者尽管疾病修饰治疗风湿病的治疗药物(DMARDs)。病人接受adalimumab 40毫克每隔一周结合甲氨蝶呤(Anti-TNF研究计划的单克隆抗体adalimumab舰队和DE019试验)或标准治疗风湿病的治疗(安全试验adalimumab在类风湿性关节炎(明星)试验)24-52周明显高于美国风湿病学院(ACR) 20日ACR50, ACR70响应率比接受安慰剂的病人+甲氨蝶呤或标准治疗风湿病的治疗。在舰队,ACR20反应达到25%,52%,和67%的adalimumab +甲氨蝶呤接受者在周1,4,分别和24。在舰队和DE019, ACR的单个组件响应的改善大大增强了adalimumab 40毫克每隔一周+甲氨蝶呤与安慰剂相比+甲氨蝶呤。单一疗法与adalimumab 40毫克每隔一周与明显高于ACR20, ACR50,比安慰剂ACR70响应率,以及明显能改善ACR的单个组件的响应。ACR的反应与adalimumab持续扩展研究的结果显示,患者接受adalimumab结合甲氨蝶呤(30个月)或作为单一疗法(5年)。伴随治疗和单药治疗试验,adalimumab与从基线明显能改善健康相关的生活质量比安慰剂(HR-QOL)措施;adalimumab也推迟结构关节损伤的影像学进展在很大程度上与安慰剂相比。Adalimumab一般耐受性良好既是伴随治疗和单药治疗。 In ARMADA, there were no significant differences between adalimumab and placebo (in combination with methotrexate) in the incidence of adverse events; however, in STAR, the incidence of injection site reactions, rash, and back pain was significantly higher with adalimumab than with placebo (in combination with standard antirheumatic therapy). No cases of tuberculosis were reported in either trial.In conclusion, subcutaneous adalimumab in combination with methotrexate or standard antirheumatic therapy, or as monotherapy, is effective in the treatment of adults with active rheumatoid arthritis who have had an inadequate response to DMARDs. Adalimumab has a rapid onset of action and sustained efficacy. The drug also retards the progression of structural joint damage, improves HR-QOL, and is generally well tolerated. Thus, adalimumab is a valuable new option for the treatment of DMARD-refractory adult rheumatoid arthritis.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Adalimumab	肿瘤坏死因子	蛋白质	人类	是的	抑制剂 抗体	细节